While the roles of Aβ and Tau in the pathogenesis of AD continue to be elucidated, researchers are monitoring changes in their levels, further exploring their potential as biomarkers of the disease, and even screening for other AD biomarkers with good predictive ability based on them (Chiu et al., 2021; Boza-Serrano et al., 2022). This evidence concerns the gene MAPT and Alzheimer disease.